US FDA approves golimumab for treating three types of immune-related arthritis

摘要

The US FDA has approved golimumab (Simponi) for the treatment of immune-related arthritis including moderate-to-severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.The drug is a new fully human monoclonal antibody (MAb) against TNF and is administered subcutaneously in combination with the immunosuppres-sant drug methotrexate in patients with rheumatoid arthritis. It also may be used with or without methotrexate for psoriatic arthritis and alone in patients with ankylosing spondylitis.